Vir Biotechnology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2016-04-07

Employees: 587

Market Cap: -

Website: http://www.vir.bio

Introduction: Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Clinical Trials

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor Malignancies
EGFR Positive Solid Tumors
EGFR

Interventions: Drug: VIR-5525
Drug: Pembrolizumab

First Posted Date: 2025-05-07

Last Posted Date: 2025-05-13

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 450

Registration Number: NCT06960395

Locations: 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇦🇺
Wollongong Hospital, Wollongong, New South Wales, Australia
🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

Phase 3

Recruiting

Conditions: Viral Hepatitis

Interventions: Drug: Tobevibart
Drug: Elebsiran

First Posted Date: 2025-03-30

Last Posted Date: 2025-05-20

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 120

Registration Number: NCT06903338

Locations: 🇲🇩
Investigative Site, Chisinau, Moldova, Republic of

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

Phase 1

Active, not recruiting

Conditions: HIV I Infection

Interventions: Biological: VIR-1388
Biological: Placebo

First Posted Date: 2023-05-11

Last Posted Date: 2024-10-10

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 95

Registration Number: NCT05854381

Locations: 🇿🇦
Setshaba Research Centre CRS, Soshanguve, Gauteng, South Africa
🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States

and more 7 locations

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

Phase 1

Active, not recruiting

Conditions: Renal Impairment

Interventions: Drug: VIR-2218

First Posted Date: 2023-05-06

Last Posted Date: 2025-04-06

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 28

Registration Number: NCT05844228

Locations: 🇺🇸
Inland Empire Clinical Trials, Rialto, California, United States
🇺🇸
Floridian Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

Phase 1

Active, not recruiting

Conditions: Hepatitis B, Chronic

Interventions: Drug: VIR-3434
Drug: TDF
Drug: VIR-2218
Drug: PEG-IFNα

First Posted Date: 2022-11-10

Last Posted Date: 2025-04-06

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 150

Registration Number: NCT05612581

Locations: 🇬🇧
Investigative Site, Manchester, United Kingdom

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Phase 2

Terminated

Conditions: Influenza A

Interventions: Biological: VIR-2482 (450 mg)
Biological: VIR-2482 (1200 mg)
Biological: Placebo

First Posted Date: 2022-10-05

Last Posted Date: 2023-09-18

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 2985

Registration Number: NCT05567783

Locations: 🇺🇸
Investigative Site, Norfolk, Virginia, United States

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Phase 1

Recruiting

Conditions: Hepatic Impairment
Cirrhosis

Interventions: Drug: VIR-2218
Drug: VIR-3434

First Posted Date: 2022-08-02

Last Posted Date: 2024-05-03

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 144

Registration Number: NCT05484206

Locations: 🇺🇸
Inland Empire Clinical Trials, Rialto, California, United States
🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Floridian Clinical Research, Miami Lakes, Florida, United States

and more 2 locations